Biovica announced that the company has signed its second US hospital agreement for DiviTum® TKa with the largest healthcare provider in Missouri, a state covering about two percent of the US population. The healthcare provider operates 18 hospitals of which one is a National Cancer Institute (NCI) Comprehensive Cancer Center and has been a partner to Biovica during the clinical development of DiviTum® TKa.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.7 SEK | +3.03% | +6.65% | -34.11% |
04-13 | Certain B Shares of Biovica International AB are subject to a Lock-Up Agreement Ending on 13-APR-2024. | CI |
04-12 | Biovica International AB Announces Divitum® Tka in Observational Trial | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.11% | 13.21M | |
-16.96% | 11.29B | |
-30.43% | 2.29B | |
-11.81% | 2.23B | |
-23.56% | 1.61B | |
+36.79% | 1.19B | |
-3.28% | 752M | |
-12.67% | 545M | |
-36.53% | 458M | |
+13.72% | 338M |
- Stock Market
- Equities
- BIOVIC B Stock
- News Biovica International AB
- Biovica Signs Second Agreement with US Healthcare Provider